Contact:

Dr. Agnes P. Olszewski
Phone: (201) 647-3757

Email: dragnes@herborium.com

Herborium Group, Inc. Signs Partnership Agreement with David Pharmaceutical Technology Corporation

TEANECK, NEW JERSEY – January 31, 2007. Herborium Group, Inc. (OTCBB: HBRM), a developer and marketer of novel botanical therapeutics®, announced today the signing of Partnership Agreement with David Pharmaceutical Technology Co., LTD (David Pharma). David Pharma, based in China, is a full-line drug discovery and development company leveraging the broad utility of patented, target-oriented Traditional Chinese Medicines (TCM) to create a new generation of safe and effective botanical therapeutic products.

David Pharma expertise includes the API (Active Pharmaceutical Ingredient), formulation development and clinical trials. The company is presently building three GMP manufacture lines including infusion, injection, and tablets. The immediate collaboration will focus on novel botanical based product development in the areas of pulmonary infection and arthritis, and on marketing of selected products on Chinese and international markets.

In addition, Herborium Group has an option to acquire an interest in David Pharma.

Dr. Agnes P. Olszewski, President and CEO of Herborium, said, “This product development and marketing related collaboration, and the proposed acquisition of an interest in David Pharma, are major steps forward in the strategic development of the Company. This will give us immediate and direct access to top quality Traditional Chinese Medicine science, innovative product leads and a rapidly growing Chinese health care market that is some analysts predict could become the world's fifth-largest pharmaceutical market.

This release and oral statements made from time to time by the Company's representatives concerning the same subject matter may contain "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by the Company with the SEC, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.